CollPlant Biotechnologies Ltd 6-K, filed May 14, 2020

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,DC 20549

Form 6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16 UNDER

THESECURITIES EXCHANGE ACT OF 1934

For the month of May 2020

Commission File Number 001-38370

CollPlantBiotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4Oppenheimer St, Weizmann Science Park

Rehovot7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

This Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163) and Form F-3 (File No. 333-229486 and 333-228054), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On May 14, 2020, CollPlant Biotechnologies Ltd. (the “Company”) convened an extraordinary general meeting of shareholders (the “Meeting”) at which the Company’s shareholders approved each of the four proposals brought before the Meeting in accordance with the majority required for each proposal.

Each of those proposals was described in the Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on April 7, 2020.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

2